148 related articles for article (PubMed ID: 33862495)
1. Lipoxygenase inhibitor ML351 dysregulated an innate inflammatory response leading to impaired cardiac repair in acute heart failure.
Tourki B; Black LM; Kain V; Halade GV
Biomed Pharmacother; 2021 Jul; 139():111574. PubMed ID: 33862495
[TBL] [Abstract][Full Text] [Related]
2. Genetic deletion of 12/15 lipoxygenase promotes effective resolution of inflammation following myocardial infarction.
Kain V; Ingle KA; Kabarowski J; Barnes S; Limdi NA; Prabhu SD; Halade GV
J Mol Cell Cardiol; 2018 May; 118():70-80. PubMed ID: 29526491
[TBL] [Abstract][Full Text] [Related]
3. Activation of EP4 receptor limits transition of acute to chronic heart failure in lipoxygenase deficient mice.
Kain V; Ingle KA; Rajasekaran NS; Halade GV
Theranostics; 2021; 11(6):2742-2754. PubMed ID: 33456570
[No Abstract] [Full Text] [Related]
4. Effects of ML351 and tissue plasminogen activator combination therapy in a rat model of focal embolic stroke.
Cheng G; Zhao W; Xin Y; Huang G; Liu Y; Li Z; Zhan M; Li Y; Lu L; van Leyen K; Liu Y
J Neurochem; 2021 May; 157(3):586-598. PubMed ID: 33481248
[TBL] [Abstract][Full Text] [Related]
5. Subacute treatment of carprofen facilitate splenocardiac resolution deficit in cardiac injury.
Halade GV; Kain V; Wright GM; Jadapalli JK
J Leukoc Biol; 2018 Dec; 104(6):1173-1186. PubMed ID: 30145840
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes.
Hernandez-Perez M; Chopra G; Fine J; Conteh AM; Anderson RM; Linnemann AK; Benjamin C; Nelson JB; Benninger KS; Nadler JL; Maloney DJ; Tersey SA; Mirmira RG
Diabetes; 2017 Nov; 66(11):2875-2887. PubMed ID: 28842399
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure.
Kain V; Jadapalli JK; Tourki B; Halade GV
Pharmacol Res; 2019 Aug; 146():104295. PubMed ID: 31216426
[TBL] [Abstract][Full Text] [Related]
8. Macrophage Specific Lipoxygenase Deletion Amplify Cardiac Repair Activating Tregs in Chronic Heart Failure.
Kain V; Grilo GA; Upadhyay G; Nadler JL; Serhan CN; Halade GV
J Leukoc Biol; 2024 May; ():. PubMed ID: 38785336
[TBL] [Abstract][Full Text] [Related]
9. Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function.
Kain V; Ingle KA; Colas RA; Dalli J; Prabhu SD; Serhan CN; Joshi M; Halade GV
J Mol Cell Cardiol; 2015 Jul; 84():24-35. PubMed ID: 25870158
[TBL] [Abstract][Full Text] [Related]
10. Interaction of 12/15-lipoxygenase with fatty acids alters the leukocyte kinetics leading to improved postmyocardial infarction healing.
Halade GV; Kain V; Ingle KA; Prabhu SD
Am J Physiol Heart Circ Physiol; 2017 Jul; 313(1):H89-H102. PubMed ID: 28411230
[TBL] [Abstract][Full Text] [Related]
11. Impact of 12/15-Lipoxygenase on Brain Injury After Subarachnoid Hemorrhage.
Gaberel T; Gakuba C; Zheng Y; Lépine M; Lo EH; van Leyen K
Stroke; 2019 Feb; 50(2):520-523. PubMed ID: 30602353
[TBL] [Abstract][Full Text] [Related]
12. Interaction of aging with lipoxygenase deficiency initiates hypersplenism, cardiac dysfunction, and profound leukocyte directed non-resolving inflammation.
Kain V; Mat Y; Halade GV
Geroscience; 2022 Jun; 44(3):1689-1702. PubMed ID: 34932185
[TBL] [Abstract][Full Text] [Related]
13. Arachidonate 5-lipoxygenase is essential for biosynthesis of specialized pro-resolving mediators and cardiac repair in heart failure.
Halade GV; Kain V; Hossain S; Parcha V; Limdi NA; Arora P
Am J Physiol Heart Circ Physiol; 2022 Oct; 323(4):H721-H737. PubMed ID: 36018758
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of 12/15 lipoxygenase by baicalein reduces myocardial ischemia/reperfusion injury via modulation of multiple signaling pathways.
Song L; Yang H; Wang HX; Tian C; Liu Y; Zeng XJ; Gao E; Kang YM; Du J; Li HH
Apoptosis; 2014 Apr; 19(4):567-80. PubMed ID: 24248985
[TBL] [Abstract][Full Text] [Related]
15. Exogenous CXCL4 infusion inhibits macrophage phagocytosis by limiting CD36 signalling to enhance post-myocardial infarction cardiac dilation and mortality.
Lindsey ML; Jung M; Yabluchanskiy A; Cannon PL; Iyer RP; Flynn ER; DeLeon-Pennell KY; Valerio FM; Harrison CL; Ripplinger CM; Hall ME; Ma Y
Cardiovasc Res; 2019 Feb; 115(2):395-408. PubMed ID: 30169632
[TBL] [Abstract][Full Text] [Related]
16. Immune responsive resolvin D1 programs myocardial infarction-induced cardiorenal syndrome in heart failure.
Halade GV; Kain V; Serhan CN
FASEB J; 2018 Jul; 32(7):3717-3729. PubMed ID: 29455574
[TBL] [Abstract][Full Text] [Related]
17. Potent and selective inhibitors of human reticulocyte 12/15-lipoxygenase as anti-stroke therapies.
Rai G; Joshi N; Jung JE; Liu Y; Schultz L; Yasgar A; Perry S; Diaz G; Zhang Q; Kenyon V; Jadhav A; Simeonov A; Lo EH; van Leyen K; Maloney DJ; Holman TR
J Med Chem; 2014 May; 57(10):4035-48. PubMed ID: 24684213
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment of carprofen impaired initiation of inflammatory- and overlapping resolution response and promoted cardiorenal syndrome in heart failure.
Krishnan V; Booker D; Cunningham G; Jadapalli JK; Kain V; Pullen AB; Halade GV
Life Sci; 2019 Feb; 218():224-232. PubMed ID: 30597172
[TBL] [Abstract][Full Text] [Related]
19. Metabolic transformation of fat in obesity determines the inflammation resolving capacity of splenocardiac and cardiorenal networks in heart failure.
Halade GV; Kain V; De La Rosa X; Lindsey ML
Am J Physiol Heart Circ Physiol; 2022 Jun; 322(6):H953-H970. PubMed ID: 35333119
[TBL] [Abstract][Full Text] [Related]
20. Immune responsive resolvin D1 programs peritoneal macrophages and cardiac fibroblast phenotypes in diversified metabolic microenvironment.
Kain V; Halade GV
J Cell Physiol; 2019 Apr; 234(4):3910-3920. PubMed ID: 30191990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
